These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 4353374)

  • 21. [Relationship between anti-arrhythmia effect and pharmacological data of Brufacaine in parenteral and oral administration in man].
    Burhorn D; Siegers CP; Diederich KW
    Verh Dtsch Ges Inn Med; 1975; 81():187-90. PubMed ID: 1229491
    [No Abstract]   [Full Text] [Related]  

  • 22. Efforts to establish an animal model of Fanconi syndrome after ifosfamide administration to rats.
    Appenroth D; Werner T; Lupp A; Patzer L; Misselwitz J; Fleck C
    J Appl Toxicol; 2007; 27(4):327-36. PubMed ID: 17265418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoglycaemic and related activities of a new pyrazolopyridine derivative (SQ 65,993).
    Polacek I; Schulze E; Burg H; Ouart J
    Arzneimittelforschung; 1974 Sep; 24(9):1242-7. PubMed ID: 4479785
    [No Abstract]   [Full Text] [Related]  

  • 24. [Comparative study of cyclophosphamide, ifosfamide and trofosfamide on Walker-256 carcinosarcoma in embryonated chicken eggs].
    Norpoth K; Witting U; Rauen HM
    Arzneimittelforschung; 1974 Jan; 24(1):86-9. PubMed ID: 4406116
    [No Abstract]   [Full Text] [Related]  

  • 25. Biopharmaceutical factors influencing LD50. I. Viscosity.
    Ritschel WA; Siegel EG; Ring PE
    Arzneimittelforschung; 1974 Jun; 24(6):907-10. PubMed ID: 4408167
    [No Abstract]   [Full Text] [Related]  

  • 26. The metabolic fate of seclazone in man.
    Edelson J; Schuster E; Shahinian S; Douglas JF
    Arch Int Pharmacodyn Ther; 1974 May; 209(1):66-74. PubMed ID: 4416360
    [No Abstract]   [Full Text] [Related]  

  • 27. [Isotope technics in studies on dilazep pharmacokinetics and metabolism in the rat].
    Schaumlöffel E; Clausnitzer M
    Arzneimittelforschung; 1972 Oct; 22(10):1643-50. PubMed ID: 4677051
    [No Abstract]   [Full Text] [Related]  

  • 28. Measurement of bile and acid kinetics by isotope dilution in man.
    Hofmann AF; Hoffman N
    Gastroenterology; 1974 Aug; 67(2):314-23. PubMed ID: 4603252
    [No Abstract]   [Full Text] [Related]  

  • 29. The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma.
    McNiel NO; Morgan LR
    Int J Clin Pharmacol Ther Toxicol; 1981 Nov; 19(11):490-3. PubMed ID: 7298241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical pharmacologic studies on 1-nitro-9-(dimethylamino)-acridine and 1-nitro-10-(dimethylaminoethyl)-9-acridone. I. Acute and subacute action.
    Pelczarska A; Kowalczyk-Bronisz SH; Blaszczyk B; Gieldanowski J; Patkowski J
    Arch Immunol Ther Exp (Warsz); 1974; 22(6):823-42. PubMed ID: 4451445
    [No Abstract]   [Full Text] [Related]  

  • 31. Modification of the alkylating ability of cyclophosphamide by fresh plasma.
    Hill BT; Harrap KR
    Chem Biol Interact; 1972 Jul; 5(2):117-25. PubMed ID: 5064934
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effects of erucic acid derivatives on the granulopexic function of the reticuloendothelial system in the rat].
    Pipy B; Gaillard D; Derache R
    Eur J Toxicol Hyg Environ; 1973; 6(3):158-67. PubMed ID: 4770295
    [No Abstract]   [Full Text] [Related]  

  • 33. The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans.
    Case DE; Reeves PR
    Xenobiotica; 1975 Feb; 5(2):113-29. PubMed ID: 1154799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical evaluation of ifosfamide in the treatment of malignant neoplasms].
    Czownicki Z; Utracka B; Till A; Styrna M
    Nowotwory; 1973; 23(3):285-90. PubMed ID: 4757587
    [No Abstract]   [Full Text] [Related]  

  • 35. Pulse intravenous cyclophosphamide for treatment of autoimmune blistering disease. Is there an advantage over oral routes?
    Werth VP
    Arch Dermatol; 1997 Feb; 133(2):229-30. PubMed ID: 9041839
    [No Abstract]   [Full Text] [Related]  

  • 36. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
    Chen L; Waxman DJ
    Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens.
    Pantarotto C; Bossi A; Belvedere G; Martini A; Donelli MG; Frigerio A
    J Pharm Sci; 1974 Oct; 63(10):1554-8. PubMed ID: 4436788
    [No Abstract]   [Full Text] [Related]  

  • 38. N-acetylcysteine: its bioavailability and interaction with ifosfamide metabolites.
    Morgan LR; Holdiness MR; Gillen LE
    Semin Oncol; 1983 Mar; 10(1 Suppl 1):56-61. PubMed ID: 6836327
    [No Abstract]   [Full Text] [Related]  

  • 39. Maternal-fetal pharmacokinetics of methanol.
    Pollack GM; Brouwer KL
    Res Rep Health Eff Inst; 1996 Jun; (74):1-48; discussion 49-53. PubMed ID: 11381741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.